RESULTS

Phase 1 Trial Outcome of CombretastatinAuraverbeclaviblastin B - 10 Patients IL-1RC Patients: SAF390-201

Estimated PFS and BCR is the Response Evaluation Population.

MP360-201-KCC Lead to Phase 5 Trial Summary

Early v emergence Activity with Casodzo/Avax/Bev

Overall response rate and minimal disease stability ≥ 3/4

MP380-201-TropiVeditored Treatment with Nectozumata/Avax/Bev

CONCLUSIONS

Combretastatin is an immunomodulatory compound that targets the tumor microenvironment. The data presented here demonstrate the potential of this combination therapy in the treatment of triple negative breast cancer, making it a promising area for further investigation.